Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough: A Systematic Review and Dose-Response Meta-Analysis.

ABSTRACT:

Importance

Gefapixant represents an emerging therapy for patients with refractory or unexplained chronic cough.

Objective

To evaluate the efficacy and tolerability of gefapixant for the treatment of adults with refractory or unexplained chronic cough.

Data sources

MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Web of Science from November 2014 to July 2023.

Study selection

Two reviewers independently screened for parallel and crossover randomized clinical trials (RCTs) that compared, in patients with refractory or unexplained chronic cough, either gefapixant with placebo, or 2 or more doses of gefapixant with or without placebo.

Data extraction and synthesis

Two reviewers independently extracted data. A frequentist random-effects do

SUBMITTER: Kum E 

PROVIDER: S-EPMC10495930 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature